Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-06
2007-11-06
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263230, C514S381000, C514S382000, C544S277000, C548S252000, C548S253000
Reexamination Certificate
active
10526388
ABSTRACT:
A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 1 106 609 (2001-06-01), None
patent: WO96/40705 (1996-12-01), None
patent: WO99/41266 (1999-08-01), None
patent: WO 01/32653 (2001-05-01), None
Garner et al., Journal of Organic Chemistry, vol. 55(12), pp. 3772-3787 (1990).
Kasnar, “Synthesis of ‘Reversed’ and ‘Double Headed’ Nucleosides,” Nucleosides & Nucleotides, vol. 14, Issue 3-5, pp. 341-344 (1995).
Walcazk et al., “Synthesis of reversed azole nucleosides under the Mitsunobu reaction conditions,” Polish J. of Chemistry 70(7), pp. 867-871 (1996).
Bouloc Natalie
Foley Fiona
Meutermans Wim
Muldoon Craig
Schafer Karl
Alchemia Limited
Anderson Rebecca
Freistein Andrew B.
Nixon & Vanderhye P.C.
LandOfFree
Compounds that interact with kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds that interact with kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds that interact with kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3854682